Dr. Amaria on Genetically Modified TILs in Melanoma
Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.
Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.
A patient with metastatic melanoma will be subjected to a biopsy or resection of their tumor. The tumor is then taken to the laboratory to grow millions of T cells, explains Amaria. Once the patient needs treatment, the T cells can then be applied in addition to high-dose IL2 to promote the sustainability of the infused T cells.
